November 29, 2018 10:06 AM EST

Boehringer axes biosimilar development outside US; MacroGenics, China's Zai Labs join forces to develop I/O treatments

ENDPOINTS

→ Germany’s Boehringer has elected to wash its hands off biosimilar development outside the United States. The decision likely comes in reaction to the painful …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Boehringer axes biosimilar development outside US; MacroGenics, China's Zai Labs join forces to develop I/O treatments

ENDPOINTS

Sign up to read this article for free.

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit says bispecific misses overall survival in closely-watched lung cancer study

Summit’s disappointing survival readout raises stakes for full data

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Boehringer ax­es biosim­i­lar de­vel­op­ment out­side US; Macro­Gen­ics, Chi­na's Zai Labs join forces to de­vel­op I/O treat­ments

ENDPOINTS

Sign up to read this article for free.

FDA ap­proves Mod­er­na’s next-gen Covid vac­cine, with lim­its on most healthy peo­ple

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

Boehringer axes biosimilar development outside US; MacroGenics, China's Zai Labs join forces to develop I/O treatments

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit says bispecific misses overall survival in closely-watched lung cancer study

Summit’s disappointing survival readout raises stakes for full data

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

From weeks to days: how Aizon Intelligent Agents transform pharma validation